OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
STAB55

Star Imaging and Path Lab Ltd

Healthcare Facilities & ServicesVerified

Star Imaging and Path Lab Ltd has a basic capital structure with no dilution risk, as shares outstanding remain unchanged at 17.42 million for both basic and diluted shares. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. Profitability metrics are not available in the valuation snapshot, and no industry_config preferred metrics are provided for comparison. The company’s financial performance relative to cohort medians remains indeterminate. The company’s revenue is concentrated in New Delhi and Uttar Pradesh, with no disclosed segment or geographic breakdown. There is no information on revenue diversification or exposure to other regions. Growth trajectory is unclear, as no numeric deltas or revenue history are provided in the outlook. The company’s future performance remains speculative without disclosed revenue trends or forward-looking guidance. Risk factors include the inability to assess liquidity risk, which may affect operational stability. No dilution risk is currently present, but the absence of financial disclosures limits the ability to evaluate long-term financial health. Recent events or filings are not disclosed in the input data, and no transcripts or source documents provide insight into management commentary or strategic direction.

30-day price · STAB+19.96 (+38.0%)
Low$49.26High$88.00Close$72.48As of15 May, 00:00 UTC
Profile
CompanyStar Imaging and Path Lab Ltd
TickerSTAB.BO
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Star Imaging and Path Lab Ltd operates pathology and diagnostic centers in New Delhi and Uttar Pradesh, offering diagnostic imaging and clinical laboratory tests for disease prediction, detection, and monitoring.

Classification. The company is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a confidence level of 0.92.

Star Imaging and Path Lab Ltd has a basic capital structure with no dilution risk, as shares outstanding remain unchanged at 17.42 million for both basic and diluted shares. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. Profitability metrics are not available in the valuation snapshot, and no industry_config preferred metrics are provided for comparison. The company’s financial performance relative to cohort medians remains indeterminate. The company’s revenue is concentrated in New Delhi and Uttar Pradesh, with no disclosed segment or geographic breakdown. There is no information on revenue diversification or exposure to other regions. Growth trajectory is unclear, as no numeric deltas or revenue history are provided in the outlook. The company’s future performance remains speculative without disclosed revenue trends or forward-looking guidance. Risk factors include the inability to assess liquidity risk, which may affect operational stability. No dilution risk is currently present, but the absence of financial disclosures limits the ability to evaluate long-term financial health. Recent events or filings are not disclosed in the input data, and no transcripts or source documents provide insight into management commentary or strategic direction.
Key takeaways
  • No dilution risk is currently present, as shares outstanding remain unchanged.
  • Liquidity risk could not be assessed due to missing balance-sheet data.
  • Revenue concentration is limited to New Delhi and Uttar Pradesh, with no further geographic diversification disclosed.
  • No financial performance metrics are available for comparison to industry benchmarks.
  • Growth trajectory and future revenue trends are indeterminate due to lack of disclosed data.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyINR
Revenue
Gross profit
Operating income
Net income
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets
Total liabilities
Total equity
Cash & equivalents
Long-term debt
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book
Net cash
Current ratio
Debt/Equity
ROA
ROE
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskUnknown
  • Liquidity risk could not be assessed (no balance-sheet inputs and no going-concern language in source documents).
Industry benchmarks
Activity: Biotechnology · cohort 9 companies
MetricSTABActivity
Op margin11.5% medp25 9.9% · p75 15.0%
Net margin8.6% medp25 6.3% · p75 12.4%
Gross margin28.8% medp25 28.8% · p75 28.8%
CapEx / revenue4.2% medp25 3.8% · p75 4.2%
Debt / equity71.3% medp25 60.7% · p75 71.3%
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-04 18:44 UTC#0209f399
Source: analysis-pipeline (hybrid)Generated: 2026-05-04 18:45 UTCJob: c0b4fcb7